Outlook Therapeutics (OTLK) Profit After Tax: 2015-2020
Historic Profit After Tax for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$9.9 million.
- Outlook Therapeutics' Profit After Tax rose 1.73% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$35.2 million, marking a year-over-year decrease of 2.07%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- As of Q3 2020, Outlook Therapeutics' Profit After Tax stood at -$9.9 million, which was down 229.09% from -$3.0 million recorded in Q2 2020.
- Outlook Therapeutics' Profit After Tax's 5-year high stood at -$1.9 million during Q4 2017, with a 5-year trough of -$22.3 million in Q2 2016.
- For the 3-year period, Outlook Therapeutics' Profit After Tax averaged around -$8.9 million, with its median value being -$9.7 million (2018).
- In the last 5 years, Outlook Therapeutics' Profit After Tax spiked by 89.94% in 2017 and then tumbled by 407.26% in 2018.
- Outlook Therapeutics' Profit After Tax (Quarterly) stood at -$19.1 million in 2016, then soared by 89.94% to -$1.9 million in 2017, then plummeted by 407.26% to -$9.7 million in 2018, then tumbled by 70.43% to -$16.6 million in 2019, then grew by 1.73% to -$9.9 million in 2020.
- Its Profit After Tax stands at -$9.9 million for Q3 2020, versus -$3.0 million for Q2 2020 and -$5.7 million for Q1 2020.